ERCC6L and pancreatic adenocarcinoma: Importantly, we observed that, in addition to OS, high levels of ERCC6L expression were associated with lower disease-specific survival and progression-free intervals in nine cancer types (i.e., ACC, BRCA, KICH, KIRC, KIRP, LGG, LIHC, LUAD, and PAAD; Figs. S8A–I and S9A–I).